Many women do not trust the health care system and will often forgo radiation and drug therapy after breast cancer surgery. That is according to a survey of 2,700 breast cancer patients by researchers at Johns Hopkins University. Lead author of the survey, Lorraine Dean, said over 30 percent skip treatments that are intended to kill any cancer cells that remain after surgery.
Contact Issels® for information on how combining conventional treatments with immunotherapy cancer treatment reduces the likelihood of relapse.
Doctor-patient trust is crucial
Cancer is a devastating disease and it is understandable that patients experience feelings of helplessness. It’s not just women with breast cancer who are losing trust in doctors and the health care system, it’s the general public as well. People often feel that doctors put their own financial interest ahead of patient care. When patients feel their doctors don’t listen to them or take their concerns seriously, trust begins to erode.
For the best possible outcome, it is necessary that doctors and patients have a strong bond of trust. Patients should feel comfortable being fully honest with health care providers and the doctors should always remember that a patient’s trust in them is a vital and necessary component of proper medical care. Each person’s cancer is unique and treatment should be based on the specific needs of each patient.
Personalized cancer treatment
At Issels®, we have been practicing individualized treatment for more than 60 years. We want you to make informed decisions about your cancer treatment options. Contact us today for more information on our autologous (from the patient’s own blood) non-toxic cancer treatment protocols.
PARP inhibitors make up a new class of cancer drugs that have been used primarily in a narrow application for women with ovarian and related forms of cancer. As presented at the European Society of Medical Oncology (ESMO) in Madrid last September, recent trial results open up possibilities of other uses.
The ARIEL-3 trial, sponsored by Clovis Oncology, involved 564 patients who received randomized doses of a placebo or Rubraca, a PARP inhibitor manufactured by Clovis. Rubraca was found to help women who had ovarian cancer both with and without BRCA mutations.
While Rubraca’s greatest effectiveness was in cases involving BRCA mutations, it also had a positive effect on some with other markers of impaired DNA repair. This condition is referred to as genomic scarring or BRCA-ness, related to a deficiency in homologous recombination repair (HRD).
Future Uses of PARP Inhibitors
Rubraca is currently approved in the U.S. for treatment of advanced BRCA-positive ovarian cancer. Based on the trial results, Clovis has applied for FDA approval of broader applications of Rubraca, including maintenance treatment. Researchers are hopeful that benefits will eventually extend to breast, pancreatic and prostate cancer.
Gene-Targeted Cancer Treatment Programs at Issels®
Gene-targeted therapies focus on blocking replication and growth of cancer cells, reducing risk to healthy cells. Contact us to learn more about cancer vaccines and other non-toxic cancer treatment programs at Issels®.
Actress Shannen Doherty is best known as one-half of the Walsh twins on the hit TV show “Beverly Hills 90210,” but lately acting has taken a back seat to a more serious challenge. For the past eighteen months Doherty has used social media to share her brave and inspiring battle against breast cancer.
Her Courageous Journey toward Restored Health
In March 2015, then 43-year-old Doherty was diagnosed with breast cancer, which she made public the following August. She filed a lawsuit against her former business managers alleging that the diagnosis was delayed because they left her without medical insurance. The suit was settled this past August.
Early in 2016, doctors discovered that the cancer had spread to Doherty’s lymph nodes, causing her to undergo a single mastectomy in May. When Doherty was presented with the American Cancer Society’s Courage Award at a gala in November, she revealed that she had completed chemotherapy and was beginning a course of radiotherapy.
Over the last year-and-a-half, Doherty has documented her treatment online in words and pictures. She credits cancer with making her a “better human being” and demonstrating which people in her life could be truly counted on, a group that includes her mother, husband and friends such as fellow actress Sarah Michelle Gellar.
Immunotherapy for Cancer: A Personalized Path of Treatment
At Issels®, our integrative immunotherapy for cancer programs are designed to address you particular needs. Our protocols attack and kill cancer cells while boosting your body’s own natural defenses. Contact us today for more information.
Cancer cells have a high-powered metabolism that demands a steady stream of nutrients for fuel. Scientists may have discovered a way to “starve” a hard-to-treat form of breast cancer by depriving the cells of a crucial substance.
Feed a Cold, Starve Cancer?
Triple negative breast cancer (TNBC) is a particularly aggressive and treatment-resistant form. In a study performed at Duke University, researchers found that the cells have an “addiction” to a nutrient called cystine, and deprivation causes them to die off quickly.
Further examination showed that the addiction is triggered by a mechanism used by the cells to migrate to other parts of the body, a process known as metastasis. According to Jen-Tsan Ashley Chi, associate professor at Duke University School of Medicine and lead author of the study, the metastasized cells are the primary target of treatment.
Chi’s group had previously published a study showing that the cells in a stubborn form of kidney cancer are also subject to the cystine addiction. The next step is to test cystine-blocking molecules on tumors and look for biomarkers that will signal cancer cells that are receptive to the treatment.
As Chi explains, tumor cells use this programming to move rapidly around the body. The researchers’ goal is to take advantage of the same process for a cure.
State-of-the-Art Immunotherapy for Cancer at Issels®
Our personally-tailored immunotherapy for cancer treatments are developed using genome testing and other cutting edge methods. Contact us for testimonials from patients who have been successfully treated for all forms of cancer, ranging from lung cancer to melanoma to leukemia.
Breast cancer is still the leading cause of death for women who suffer from cancer, but early detection can improve the chances of successful treatment. In 2016 a group of researchers identified a molecular marker that can indicate a woman’s risk for developing the disease.
Identifying a Common Thread
The study was conducted by a joint team from Harvard Stem Cell Institute (HSCI), Dana-Farber Cancer Institute (DFCI), and Brigham and Women’s Hospital (BWH). Researchers reviewed biopsies from 302 women who had been diagnosed with benign breast disease. Some of the biopsies dated back to 40 years ago.
Out of this group, 69 women later developed cancer and 233 did not. It was discovered that women with a higher percentage of a particular marker were more likely to develop cancer.
Ki67 is a molecular marker found in the lining of the mammary ducts and milk-producing lobules that identifies proliferating cells. These tissues are the site where most breast cancers develop.
The Present and Future of Ki67 Testing
While Ki67 testing is already being used to determine courses of treatment, this discovery will allow doctors to test precancerous tissue for use as a predictive tool. The method could help avoid some of the drawbacks of mammograms, which are currently the best option for early detection.
Immunotherapy for Cancer: A Personalized Method of Treatment
Genomic testing is just one of the specialized tools we use to create our individually tailored therapies targeted to meet your personal needs. Contact us to learn why Issels® is the leader in non-toxic and effective immunotherapy for cancer.
Vitamin D has long been known as an essential nutrient that aids your bones with calcium absorption. A recent study shows that there may also be a link between vitamin D levels and surviving breast cancer.
Examining the Link between Vitamin D and Breast Cancer Survival
The study, performed by a research team from the Roswell Park Cancer Institute in Buffalo, began in 2006 with a group of women from California who had been diagnosed with invasive breast cancer. Participants were divided into three sub-groups based on blood levels of a particular vitamin D marker.
Women with more advanced cancers tended to have low levels of the marker. Over an average of seven years of follow-up, 100 of these women died compared to 76 women with high levels. There were approximately 1,600 women total involved in the study.
In addition, women with the highest vitamin D levels were 28 percent less likely to die of any cause, once factors such as tumor characteristics were accounted for. This link was the strongest among pre-menopausal women.
What Does This Mean for the Future?
According to lead author Song Yao, overall results showed “30 percent reduction of all-cause mortality” linked to vitamin D levels at the time of diagnosis. While the study supports previous research linking vitamin D with breast cancer survival, Yao said a randomized controlled trial would be needed to determine a direct cause-and-effect.
Immunotherapy for Cancer: Going Beyond Traditional Treatments
Immunotherapy for cancer has been gaining a lot of attention recently, but at Issels® we have a decades-long history of using these state-of-the-art methods successfully. Contact us for more information.